Berkley Psytech Raised $100M

Your "Unfair Advantage" Isn't a Secret, It's Your Story

Every founder is told to find an "unfair advantage." For Cosmo Feilding Mellen, that advantage wasn't a patent or a piece of code—it was his entire life. Born to "unconventional parents" who were central figures in the first psychedelic renaissance, his upbringing gave him a depth of understanding and a network that couldn't be bought.

His father quit a 60-cigarette-per-day habit cold after a single psychedelic experience. His mother, after years of activism, founded the Beckley Foundation from their home to legitimize the study of psychoactive compounds and advocate for sensible drug policy. Mellen grew up surrounded by the very subject he would later build multiple companies around.

Your unique background—the niche interests, the family history, the non-traditional career path—is not a liability. It is the source of your most authentic and powerful insights. Don't hide it. Build your company's narrative around it. This is the one thing your competitors can never copy.

How to De-Risk a Controversial Idea

Psychedelics were (and in many ways still are) a fringe topic. Mellen’s mother discovered that as a lone activist, it was nearly impossible to be taken seriously. The solution was to stop being an individual and start being an institution.

Common Mistake: The Lone Crusader

Many founders in emerging fields try to carry the entire weight of their mission alone. They believe their passion is enough to convince the world. This approach is exhausting and rarely works. You end up looking like a rogue, not a revolutionary.

The Fix: Institutionalize Your Mission

The Beckley Foundation was a strategic masterstroke. By creating a formal non-profit, Mellen's mother could:

Attract Credible Partners: Top scientists, drug policy experts, and politicians who would never align with a single activist were willing to join the board of a formal foundation. · Create an "Air Cover" of Legitimacy: The foundation focused on two things: sparking scientific research and promoting evidence-based policy. This sober, academic framing provided a safe container for a controversial topic. · Shift the Narrative: It was no longer about one person's belief; it was about an institution's research. This allowed them to build a powerful network and a body of work that would become the bedrock of Mellen's future companies.

If you are operating in a new or contentious space, your first product might not be a piece of software, but a vehicle for legitimacy. Consider a foundation, a research institute, or an open-source consortium to build credibility before you build a business.

The "Stepping Stone" Exit: Using a Small Win to Fund a Big Vision

Mellen first translated his mission into commerce with Beckley Canopy Therapeutics. But he didn't try to boil the ocean. Instead, he executed a classic "stepping stone" strategy.

Find Your "Adjacent Industry" Partner

Mellen knew the science, but he needed commercial drug development expertise. He found it in Mark Wayne, a pioneer in the Canadian cannabis industry whose company had become the largest in the world. Cannabis was an adjacent, more mature market that had already navigated legalization and public markets. The partnership was a perfect fit.

Subject: My work in [Your Field], your playbook in [Their Field]

I've been following your work at [Their Company] for years. The way you navigated the regulatory and commercial challenges in the [Their Industry] space was groundbreaking.

I'm the founder of [Your Company], where we are tackling a similar set of challenges in the emerging [Your Industry] space. My expertise is on the [Science/Product] side, but I see a direct parallel between the path you forged and the one we have ahead of us.

I believe a partnership could be uniquely effective. Would you be open to a brief 20-minute call next week to discuss the parallels I see?

The Math That Matters: An $80M Stepping Stone

Beckley Canopy Therapeutics raised $10M and was acquired for $80M. For investors, this 8x return on capital is a fantastic outcome. But for Mellen, it was more than just a financial win. It was proof.

It Proved the Thesis: The exit validated that there was real commercial demand for psychedelic-based therapeutics. · It Proved the Team: It showed that Mellen and his partners could execute, navigate a regulated industry, and deliver a return. · It Funded the Real Vision: The proceeds gave Mellen and his early backers the capital and confidence to swing for the fences with his next venture.

The Harsh Reality of Pharma vs. Tech

Do not confuse this with a SaaS startup. Developing a novel pharmaceutical is a brutal, decade-long, capital-intensive marathon. The goal of Beckley Psytech is not to ship an MVP and iterate. It is to run rigorous, multi-phase clinical trials to create FDA-approved medicines. The $100M Mellen raised isn't a growth round; it's the necessary ante to even play the game. Founders entering this space must be prepared for a radically different timeline and risk profile than a typical tech venture.

Leveraging Your Exit Into a $100M War Chest

When Mellen went to raise money for his next idea, Beckley Psytech, the conversation was different. He wasn't selling an idea; he was selling a track record. The previous investors who made significant money from the $80M exit were happy to back him again.

He set up the new company in 2019 and by 2021 had closed an oversubscribed $100M Series B. An "oversubscribed" round means more investors wanted in than you had room for—it's a massive signal of strength.

Your first successful exit is the single most powerful fundraising tool you will ever have. It replaces every slide about "market potential" and "hockey-stick projections" with a simple, undeniable fact: "I have done this before. I have made my investors money. I will do it again, but bigger."

Your Pitch Deck is Just a Prop; Your Narrative is Everything

The original article notes that "storytelling is everything" and that capturing your essence in 15-20 slides is key. This is true, but it misses the point. The pitch deck isn't the story. It's a prop used to tell the story you have been building for years.

Mellen's journey from filmmaker (making a #1 Netflix documentary) to founder is telling. He has always been a storyteller. His pitch for Beckley Psytech wasn't a 20-slide deck created in a week. It was the culmination of his family's 50-year history, the foundation's scientific credibility, the successful $80M exit, and a clear, audacious vision for the future of medicine.

How to Apply These Lessons This Week

Map Your Unfair Advantage: Write down the 3-5 most unusual or non-obvious parts of your background, network, or personal history. How can you build your company's story around them instead of hiding them? · Draft Your "Institutionalize" Plan: If you're in a new or controversial space, spend one hour outlining what a non-profit, research paper, or expert council would look like. Who are the top 5 credible experts you would want on your board? · Identify Three Adjacent Partners: List three people who have successfully built a business in an industry that was once where yours is now. Draft a "parallel path" outreach email to one of them. · Define Your "Stepping Stone" Exit: What is the smaller, faster win you could achieve in the next 2-3 years that would prove your model and give you the credibility to raise for your ultimate vision? Be specific about the capital needed and the target outcome.